Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1 to 10 of 2440 total matches.
Donislecel (Lantidra) for Type 1 Diabetes
The Medical Letter on Drugs and Therapeutics • Apr 15, 2024 (Issue 1700)
Donislecel (Lantidra) for Type 1 Diabetes ...
The FDA has approved donislecel-jujn (Lantidra –
CellTrans), an allogeneic pancreatic islet
cellular therapy, for use in conjunction with
immunosuppression for treatment of adults with
type 1 diabetes who are unable to approach target
HbA1c because of current repeated episodes of
severe hypoglycemia despite intensive diabetes
management and education. Donislecel is the first
cell-based treatment to be approved in the US for
type 1 diabetes.
Med Lett Drugs Ther. 2024 Apr 15;66(1700):63-4 doi:10.58347/tml.2024.1700d | Show Introduction Hide Introduction
Ozenoxacin 1% Cream (Xepi) for Impetigo
The Medical Letter on Drugs and Therapeutics • Apr 22, 2019 (Issue 1570)
Ozenoxacin 1% Cream (Xepi) for Impetigo ...
The FDA has approved a 1% cream formulation
of ozenoxacin (Xepi – Cutanea), a nonfluorinated
quinolone antibiotic, for treatment of impetigo caused
by Staphylococcus aureus or Streptococcus pyogenes
in patients ≥2 months old.
Cabotegravir/Rilpivirine (Cabenuva) for HIV-1 Infection
The Medical Letter on Drugs and Therapeutics • May 31, 2021 (Issue 1625)
Cabotegravir/Rilpivirine (Cabenuva) for HIV-1 Infection ...
The FDA has approved Cabenuva (ViiV Healthcare),
an extended-release formulation of the new integrase
strand transfer inhibitor (INSTI) cabotegravir
copackaged with an extended-release formulation
of the non-nucleoside reverse transcriptase inhibitor
(NNRTI) rilpivirine, as a once-monthly complete
regimen for intramuscular (IM) treatment of adults
with HIV-1 infection who are virologically suppressed
(HIV-1 RNA...
Tirbanibulin 1% Ointment (Klisyri) for Actinic Keratosis
The Medical Letter on Drugs and Therapeutics • May 03, 2021 (Issue 1623)
Tirbanibulin 1% Ointment (Klisyri) for Actinic Keratosis ...
Tirbanibulin, a microtubule inhibitor, has been
approved by the FDA as a 1% ointment (Klisyri –
Almirall) for topical treatment of actinic keratosis of
the face or scalp.
Two New GLP-1 Receptor Agonists for Diabetes
The Medical Letter on Drugs and Therapeutics • Nov 10, 2014 (Issue 1455)
Two New GLP-1 Receptor Agonists for Diabetes ...
Two new injectable GLP-1 (glucagon-like peptide-1)
receptor agonists, dulaglutide (Trulicity [trū li si tee] –
Lilly) and albiglutide (Tanzeum [tan' zee um] – GSK),
have been approved by the FDA for once-weekly
treatment of type 2 diabetes. Other available GLP-1
receptor agonists include exenatide, which is approved
for injection twice daily (Byetta) or once weekly
(Bydureon), and liraglutide (Victoza), which is injected
once daily.
Teplizumab (Tzield) to Delay Onset of Type 1 Diabetes
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023 (Issue 1667)
Teplizumab (Tzield) to Delay Onset of Type 1 Diabetes ...
Teplizumab-mzwv (Tzield – Provention Bio), an anti-CD3 monoclonal antibody, has been approved by the
FDA to delay the onset of stage 3 type 1 diabetes
in patients ≥8 years old who have stage 2 type 1
diabetes. It is the first drug to become available in the
US that delays the onset of type 1 diabetes.
Med Lett Drugs Ther. 2023 Jan 9;65(1667):7-8 doi:10.58347/tml.2023.1667c | Show Introduction Hide Introduction
In Brief: GI Effects of GLP-1 Receptor Agonists
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023 (Issue 1690)
In Brief: GI Effects of GLP-1 Receptor Agonists ...
Glucagon-like peptide-1 (GLP-1) receptor agonists and
the dual glucose-dependent insulinotropic polypeptide
(GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro) are widely prescribed for treatment of type 2 diabetes
and weight management (see Table 1), but they delay
gastric emptying and commonly cause nausea and
vomiting. Gastroparesis and bowel obstruction (ileus)
have also been reported with their use.
Med Lett Drugs Ther. 2023 Nov 27;65(1690):191-2 doi:10.58347/tml.2023.1690e | Show Introduction Hide Introduction
Cabotegravir (Apretude) for HIV-1 Pre-Exposure Prophylaxis
The Medical Letter on Drugs and Therapeutics • Feb 21, 2022 (Issue 1644)
Cabotegravir (Apretude) for HIV-1 Pre-Exposure Prophylaxis ...
The FDA has approved Apretude (ViiV Healthcare),
an IM extended-release (ER) formulation of the integrase
strand transfer inhibitor (INSTI) cabotegravir,
for use every 2 months to prevent sexually acquired
HIV-1 infection in at-risk adolescents and adults.
Apretude is the first ER formulation to be FDA-approved
for pre-exposure prophylaxis (PrEP) of
HIV-1 infection.
Insulin-like Growth Factor-1 for Severe Growth Failure
The Medical Letter on Drugs and Therapeutics • May 20, 2007 (Issue 1261)
Insulin-like Growth Factor-1 for Severe Growth Failure ...
Mecasermin (Increlex - Tercica), which is injected subcutaneously, has been approved by the FDA for treatment of growth failure in children with severe primary insulin-like growth factor (IGF-1) deficiency. Mecasermin is recombinant human (rh) IGF-1. It has also been approved to treat children with short stature who are deficient in growth hormone (GH), but have developed neutralizing antibodies in response to GH treatment. A similar product, mecasermin rinfabate (Iplex - Insmed), that was approved by the FDA for the same indications was withdrawn from the market due to patent...
Dolutegravir/Lamivudine (Dovato) - A Two-Drug Complete Regimen for HIV-1 Infection
The Medical Letter on Drugs and Therapeutics • Aug 26, 2019 (Issue 1579)
Dolutegravir/Lamivudine (Dovato) - A Two-Drug Complete Regimen for HIV-1 Infection ...
The FDA has approved Dovato (ViiV), a fixed-dose
combination of the integrase strand transfer inhibitor
(INSTI) dolutegravir (Tivicay) and the nucleoside
reverse transcriptase inhibitor (NRTI) lamivudine
(Epivir, and generics), as a once-daily complete
regimen for treatment of adults with HIV-1 infection
who are antiretroviral-treatment naive and have no
known substitutions associated with resistance
to either drug. Dolutegravir/lamivudine is the first
complete regimen to be approved by the FDA for
initial treatment of HIV-1 infection that contains 2
rather than 3 antiretroviral...